Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Cochrane on Value of TPO Mimetics for MDS

Cochrane; 2017 Sep 29; Dodillet, Kreuzer, et al

Publish date:: October 15, 2017

Thrombopoietin (TPO) mimetics led to fewer bleeding events than placebo in patients with myelodysplastic syndrome (MDS), according to a Cochrane review of 8 studies involving 746 individuals. However, there appeared to be no mortality differences. Among the specific findings, based on moderate quality evidence:

TPO mimetics probably decrease the number of patients having bleeding events. 71% of patients taking placebo experienced such events, vs 66% of those taking TPO mimetics.
No difference was seen in terms of mortality, transformation to acute myeloid leukemia, transfusion requirement, adverse events, and serious adverse events.
No trial evaluated quality of life.

Citation:

Dodillet H, Kreuzer K, Monsef I, Skoetz N. Thrombopoietin mimetics for patients with myelodysplastic syndromes. Cochrane Database of Syst Rev. 2017, Issue 9. Art. No.: CD009883. doi:10.1002/14651858.CD009883.pub2.

This Week's Must Reads

Phase II Trial of DNA Vaccine Encoding PAP in Patients with PCa ,

Utilization of Surgery for Post-prostatectomy Incontinence,

Claims Analysis of Advanced PCa Treatment Costs and Resource Use,

Testosterone Therapy Doesn't Increase Prostate Cancer Risk,

Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced PCa,

Must Reads in AML

Immune system changes play a role in AML relapse, Christopher MJ et al. N Engl J Med. 2018 Oct 31. doi: 10.1056/NEJMoa1808777.

Venetoclax plus HMA studied in AML, DiNardo C et al. Blood. 2018 Oct 25. doi: 10.1182/blood-2018-08-868752.

T cell infusion effective in PML, Muftuoglu M et al. N Engl J Med. 2018 Oct 11;379:1443-51

Higher AML, MDS risk linked to autotransplants, Radivoyevitch T et al. Leuk Res. 2018 Jul 19. pii: S0145-2126(18)30160-7

Tibsovo for AML with IDH1 mutation, FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation, FDA press release